摘要
目的以利培酮为对照,探讨奎硫平治疗首发精神分裂症的疗效和副作用。方法将78例符合CCMD-3和DSM-Ⅳ的精神分裂症诊断标准的首发病人随机分为两组,分别给予奎硫平和利培酮治疗8周。在治疗前及治疗2、4、6、8周时采用阳性症状和阴性症状量表(PANSS)评定临床疗效,副反应量表(TESS)评定副反应。结果治疗8周后的疗效近似(P>0.05);奎硫平组和利培酮组的显效率差异无显著性(P>0.05);奎硫平组的副反应发生率低于利培酮组,但差异无显著性(P>0.05)。利培酮组锥体外系副反应和内分泌改变的发生均明显高于奎硫平组(P<0.05)。两药的副作用均以轻、中度多见。结论奎硫平和利培酮对首发精神分裂症的疗效相当,依从性好,副作用方面有一定的差异。
OBJECTIVE To research the therapeutic and side effects of quetiapine in the treatment of first- run schizophrenic out.patients.METHOD 78 schizophrenic patients by CCMD- 3 and DSM-Ⅳ were randomly allocated to two groups treated with quetiapine and risperidone for 8 weeks,the positive and negative symptoms scale(PANSS) and the treatment emergent symptoms scale(TESS) were used to evaluate efficacy and adverse effects respectively before and at the ends of 2,4,6,8 weeks of treatment.RESULTS The total efficacy rate for the quetiapine and risperidone groups were 92.31%and 89.74%after 8 weeks.There was no significant difference between the two groups(P >0.05).Incidence of adverse effects in the quetiapine group was lower than that in the risperidone group,but the difference was not significant(P > 0.05).The rate of extrapyramidal symptoms and endocrine change were significantly higher in the risperidone group than those in the quetiapine group(P <0.05).While these side effects were not serious.CONCLUSIONS The results suggest that quetiapine is as effective as resperidone for the treatment of first- run schizophrenia.but two agents have different side effects profile,and patients often had good torlerability for them.
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2005年第z3期883-885,共3页
Chinese Journal of Modern Applied Pharmacy
关键词
奎硫平
利培酮
门诊
首发精神分裂症
quetiapine
risperidone
out-patient
first-run schizophrenia
